Cytek Biosciences, Inc.

DB:8EQ Stock Report

Market Cap: €858.8m

Cytek Biosciences Balance Sheet Health

Financial Health criteria checks 5/6

Cytek Biosciences has a total shareholder equity of $385.5M and total debt of $3.2M, which brings its debt-to-equity ratio to 0.8%. Its total assets and total liabilities are $491.2M and $105.8M respectively.

Key information

0.8%

Debt to equity ratio

US$3.23m

Debt

Interest coverage ration/a
CashUS$277.78m
EquityUS$385.46m
Total liabilitiesUS$105.76m
Total assetsUS$491.23m

Recent financial health updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 8EQ's short term assets ($390.2M) exceed its short term liabilities ($62.8M).

Long Term Liabilities: 8EQ's short term assets ($390.2M) exceed its long term liabilities ($43.0M).

Debt to Equity History and Analysis

Debt Level: 8EQ has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 8EQ's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 8EQ has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 8EQ is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 8.5% per year.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y